

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Canceled)
2. (Currently Amended) A method of activating the differentiation of neural cells in an injured brain or spinal cord comprising the steps of: transplanting bone marrow cells into a penumbra central nervous tissue adjacent to the an injured brain cells or spinal cord tissue; and activating the endogenous central nervous system stem cells to differentiate into neurons.
3. (Currently Amended) A method of treating injured brain or spinal cord cells comprising the steps of: transplanting cultured bone marrow cells into a penumbra central nervous tissue near the injured brain cells; and generating new neurons at the location of transplantation or of intravascular injection of cultured bone marrow cells.
4. (Currently Amended) A method of treating injured brain or spinal cord in a patient by injecting or transplanting a composite of mesenchymal stem cells (MSCs) and neurospheres into a penumbra central nervous tissue adjacent to an impaired nervous tissue of the patient in order to activate endogenous stem cells in the brain to differentiate into parenchymal cells.
5. (Currently Amended) A method of treating a patient suffering from a brain or spinal cord injury or neurodegenerative disease, the method comprising administering cultured bone marrow stromal cells into a central nervous tissue adjacent to an impaired nervous tissue of the patient in order to activate endogenous stem cells in the brain to differentiate into

parenchymal cells~~The method of claim 1~~, wherein the central nervous tissue adjacent to the impaired nervous tissue comprises an penumbral tissue.

6. (Currently Amended) A method of treating a patient suffering from a brain or spinal cord injury or neurodegenerative disease, the method comprising administering cultured bone marrow stromal cells into a central nervous tissue adjacent to an impaired nervous tissue of the patient in order to activate endogenous stem cells in the brain to differentiate into parenchymal cells~~The method of claim 1~~, wherein the central nervous tissue adjacent to the impaired nervous tissue comprises an ischemic boundary zone.

7. (Currently Amended) A method of treating a patient suffering from a brain or spinal cord injury or neurodegenerative disease, the method comprising administering cultured bone marrow stromal cells into a central nervous tissue adjacent to an impaired nervous tissue of the patient in order to activate endogenous stem cells in the brain to differentiate into parenchymal cells~~The method of claim 1~~, wherein the cells are administered to the central nervous tissue adjacent to an impaired nervous tissue by way of intravascular administration.

8. (Currently Amended) The method of claim 4~~5~~, wherein the cells are administered to the central nervous tissue adjacent to an impaired nervous tissue by way of direct transplantation.

9. (Currently Amended) The method of claim 4~~5~~, wherein the impaired nervous tissue comprises a brain tissue.

10. (Currently Amended) The method of claim 4~~5~~, wherein the impaired nervous tissue comprises a spinal cord tissue.

11. (Currently Amended) The method of claim 4~~5~~, wherein the impaired nervous tissue comprises a lesion and further wherein the ~~cells are administered into a penumbral tissue~~ is adjacent to the lesion.

12. (Currently Amended) The method of claim 4~~5~~, wherein the impaired nervous tissue comprises a lesion and further wherein the ~~cells are administered into~~ penumbral tissue is an ischemic boundary zone adjacent to the lesion.

13. (Currently Amended) The method of claim 4~~5~~, wherein the impaired nervous tissue comprises a tissue affected by stroke.

14. (Currently Amended) The method of claim 4~~5~~, wherein the neurodegenerative disease is Parkinson's disease.

15. (Previously Presented) The method of claim 3, wherein the location of intravascular injection is intraarterial.

16. (Previously Presented) The method of claim 3, wherein the location of intravascular injection is intravenous.